NCT06963502 - A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

762

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

April 30, 2030

Conditions

Advanced Solid TumorsColorectal CancerNon-Small Cell Lung Cancer

Interventions

DRUG

HS-10370

Participants will receive HS-10370 dose 1 administered orally

DRUG

HS-20117

Participants will receive HS-20117 given as dose 3 intravenous infusion(IV) once every 14-day cycle.

DRUG

Adebrelimab

Participants will receive Adebrelimab intravenous infusion(IV) once every 21-day cycle

DRUG

Capecitabine

Participants will receive Capecitabine administered orally

DRUG

Oxaliplatin

Participants will receive Oxaliplatin intravenous infusion(IV) once every 21-day cycle.

DRUG

Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan

Participants will receive Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan intravenous infusion(IV) once every 14-day cycle.

DRUG

HS-20093

Participants will receive HS-20093 intravenous infusion(IV) once every 21-day cycle

DRUG

platinum (cisplatin or carboplatin)

Participants will receive platinum (cisplatin or carboplatin) administered IV in 21-day cycles.

Trial Locations (2)

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

Sun Yat-sen University Cancer Center, Shanghai